Application of circRNA-Slc8a1 as a new target in the diagnosis and treatment of diabetic nephropathy
By detecting and inhibiting the expression of circRNA-Slc8a1, the problem of unclear renal fibrosis mechanism of diabetic nephropathy was solved, and its participation mechanism in DKD was discovered, and new diagnostic and therapeutic targets were provided, with the protection of renal tubular epithelial cells. Effect.
Patent Information
- Application Number
- CN202311156412.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-08
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-09-08
AI Technical Summary
The mechanism of renal fibrosis in diabetic nephropathy is unclear, the existing technology is difficult to effectively prevent and treat, and the relationship between circular RNA circRNA-Slc8a1 and ferrodys and fibrosis is not clear.
By detecting and inhibiting the expression of circRNA-Slc8a1, using it to develop diagnostic and therapeutic methods for new targets, including biomarker detection and application of expression inhibitors, the siRNA sequences are 5'-GAUGAAAUAGUGUUGGAGC-3' and 5'-GCUCCAACACUAUUUCAUC-3 ', inhibit the expression of circRNA-Slc8a1 to slow down fibrosis and iron death in renal tubular epithelial cells.
Through research, it was found that circRNA-Slc8a1 promotes fibrosis and ferrous death in renal tubular epithelial cells. Knocking down circRNA-Slc8a1 has a protective effect, providing a new target for the diagnosis and treatment of diabetic nephropathy, and clarifying its participation mechanism in DKD.
Smart Images

Figure BDA0004438722660000051 
Figure BDA0004438722660000052 
Figure BDA0004438722660000053
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to the application of circular RNA circRNA-Slc8a1 as a new target in the diagnosis and treatment of diabetic nephropathy. Background Art
[0002] Diabetic Kidney Disease (DKD) is the most common complication of diabetes and the leading cause of end-stage renal disease (ESRD) worldwide. DKD accounts for nearly 50% of new cases of ESRD in developed countries worldwide. TEC fibrosis plays a key role in the process of renal fibrosis and is considered to be a sign of the initiation of renal fibrosis. A variety of factors can lead to the occurrence of renal fibrosis in diabetic nephropathy, such as ferroptosis, oxidative stress, mitochondrial dysfunction, autophagy dysfunction, and activation of inflammatory pathways, but the specific mechanism remains unclear.
[0003] Ferroptosis is a new type of programmed cell death in which iron-dependent lipid peroxides accumulate to lethal levels. It is closely related to iron metabolism, lipid metabolism, and the amino acid antioxidant system. Ferroptosis plays an important role in the development of renal fibrosis and may become a potential target for the prevention and treatment of renal fibrosis.
[0004] Circular RNA (circRNA) is a special type of non-coding RNA molecule (sometimes expressed in vivo). CircRNA can participate in aggravating or delaying renal fibrosis through oxidative stress, ECM deposition, inflammation, apoptosis, pyroptosis, etc., and is closely related to the progression of DKD. However, its relationship with ferroptosis and fibrosis needs further study.
[0005] Solute carrier family 8 member A1 (SLC8A1) is a bidirectional ion transporter that is a Na + / Ca 2+ The exchanger, the most ubiquitously expressed member of the SLC family, is expressed at low levels in most tissues and at high levels in the brain and kidney. Summary of the invention
[0006] The purpose of the present invention is to address the above problems and provide a circular RNA circRNA-Slc8a1 as a new target for use in the diagnosis and treatment of diabetic nephropathy.
[0007] In order to achieve its purpose, the present invention adopts the following technical solution:
[0008] The invention discloses a method for preparing a product for diagnosing diabetic nephropathy by using a reagent for detecting a biomarker in a sample, wherein the biomarker is circRNA-Slc8a1.
[0009] In the application technology scheme, the expression level of circRNA-Slc8a1 in patients is upregulated compared with normal controls.
[0010] In the application technology scheme, the content of circRNA-Slc8a1 in the patient's test sample is detected by total RNA extraction, reverse transcription, and quantitative PCR.
[0011] The present invention also provides the use of a circRNA-Slc8a1 expression inhibitor in the preparation of a drug for preventing and treating diabetic nephropathy.
[0012] In the application technology scheme, the circRNA-Slc8a1 expression inhibitor includes siRNA.
[0013] In the application technology scheme, the sequence of the siRNA is:
[0014] Sense strand sequence: 5'-GAUGAAAUAGUGUUGGAGC-3',
[0015] Antisense strand sequence: 5′-GCUCCAACACUAUUUCAUC-3′.
[0016] The present invention also provides the use of circRNA-Slc8a1 as a target in screening drugs for preventing and treating diabetic nephropathy.
[0017] In the application technology scheme, the drug inhibits the expression of circRNA-Slc8a1.
[0018] In the above-mentioned application technology scheme, the transcription nucleotide sequence of circRNA-Slc8a1 is shown in SEQ ID NO.1.
[0019] In the application technology scheme, circRNA-Slc8a1 promotes EMT-induced fibrosis and ferroptosis of renal tubular epithelial cells.
[0020] The beneficial effects of the present invention are as follows: by studying the circRNAs that are specifically highly expressed in renal tubular epithelial cells under high glucose conditions, it is found that circRNA-Slc8a1 promotes EMT-induced fibrosis and ferroptosis of renal tubular epithelial cells, and knocking down circRNA-Slc8a1 has a protective effect on renal tubular epithelial cells, and is expected to be a potential target for the diagnosis and treatment of DN. It clarifies the mechanism by which it is involved in the occurrence and development of DKD, and provides a scientific basis for new targets for the diagnosis or treatment of DKD. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 Screening and validation of circSlc8a1 in diabetic nephropathy mice; AC: Comparison of body weight, blood glucose, and urine albumin to creatinine ratio between normal mice and DN mice; D: Staining of kidney tissues of normal mice and DN mice; E: Heat map analysis of sequencing results; F: Fluorescent immunoblot assay of kidney tissues of normal mice and DN mice; G: qRT-PCR detection of circSlc8a1 expression levels in cells; HI: Fluorescent immunoblot assay and nuclear-cytoplasmic separation assay to detect the distribution of circSlc8a1 in TCMK1 cells.
[0022] Figure 2 are the results of RNA-seq sequencing analysis of overexpressed circSlc8a1. AB: Heat map analysis and GO analysis of RNA-seq results after overexpression of circSlc8a1 in TCMK1 cells.
[0023] Figure 3 This is the analysis of the effect of knockdown / overexpression of circSlc8a1 on EMT-induced fibrosis in renal tubular epithelial cells. A: efficiency detection of knockdown / overexpression of circSlc8a1; BD: WB and IF experiments to detect the expression levels of Fn, E-Ca, N-Ca, α-SMA, TGFβ-1, and Vimentin proteins.
[0024] Figure 4 Analysis of the effect of knockdown / overexpression of circSlc8a1 on ferroptosis of renal tubular epithelial cells. A: Detection of the efficiency of knockdown / overexpression of circSlc8a1; BF: Detection of ferrous ions, MDA content, GSH content, ROS, and SOD activity after knockdown / overexpression of circSlc8a1; GH: WB and IF detection of Tfr, xCT, Vdac1, and Gpx4 protein contents. DETAILED DESCRIPTION
[0025] The present invention will be further described below in conjunction with embodiments, but the present invention is not limited thereto.
[0026] The experimental methods in the following examples are all conventional methods unless otherwise specified; the materials and reagents used are all conventional materials and reagents in the art and are commercially available unless otherwise specified.
[0027] Example 1
[0028] 1 Materials and methods
[0029] 1.1 Materials
[0030] Type 2 diabetes mellitus (T2DM) model mice: db / db mice; control normal mice: db / dm mice. The SPF mice used in the above experiments were purchased from the Model Animal Research Institute of Nanjing University. Immortalized mouse renal tubular epithelial cells TCMK1 were purchased from the Cell Bank of the Chinese Academy of Sciences. Anti-rabbit Fn antibody (purchased from abcam, catalog number ab199056), anti-mouse E-Ca antibody (purchased from abcam, catalog number ab231303), anti-mouse N-Ca antibody (purchased from abcam, catalog number ab76011), anti-rabbit α-SMA antibody (purchased from CST, catalog number #48938), anti-rabbit Tgfβ-1 antibody (purchased from abcam, catalog number ab215715), anti-rabbit Vimintin antibody (purchased from abcam, catalog number ab8978), anti-rabbit Gpx4 antibody (purchased from ABclonal, catalog number A1933), anti-rabbit xCT antibody (purchased from ABclonal, catalog number A2413), anti-rabbit Vdac1 antibody (purchased from abcam, CatNo.66345-1-Ig), and anti-rabbit Tfr antibody (purchased from ABclonal, catalog number A5865).
[0031] 1.2 Methods
[0032] 1.2.1 Modeling and grouping
[0033] Three 12-week-old db / db mice were randomly selected as the experimental group and three db / dm mice were selected as the control group (all experimental mice were raised in an environment with free access to drinking water and standard feed, constant temperature, and 12-hour alternating lighting. The animal operation standards of the ethics committee were strictly followed). The RNA of the kidney tissue was extracted for sequencing. After being sent for inspection, one of the mice in the normal group failed the quality control and was therefore eliminated (db / db, n=3; db / dm, n=2). Relevant literature studies have shown that after one sample is eliminated due to quality control, the testing of other samples is in line with statistical principles. The two groups as normal groups do not affect subsequent experimental studies. 1.2.2 Determination of body weight, blood sugar, urine protein, and creatinine
[0034] The body weight of the test mice was recorded starting from 8 weeks of age; blood was collected from the tail vein of the mice after 6 hours of fasting without water or food for blood glucose concentration measurement; urine samples of the mice were collected for 24 hours to measure urine protein and creatinine.
[0035] 1.2.3 HE, PAS, and Masson staining
[0036] The mice were anesthetized and killed, and the kidney tissues were fixed in 4% formaldehyde and completely immersed. After 1 day, the sections were routinely paraffin-embedded and sliced. The sections were dewaxed and dehydrated, then rehydrated with graded alcohol for 3 minutes, stained with hematoxylin, washed, differentiated, dehydrated with alcohol, stained separately, and observed under a microscope after sealing.
[0037] 1.2.4DN tissue total RNA extraction, sequencing and verification
[0038] Trizol was used to extract total RNA from DN kidney tissue and the concentration was measured. Its A260 / 280 was in the range of 1.79-1.99, and the peak was high and fell in the range of 260-270. The purified and prepared tissue RNA samples were then stored in dry ice and sent to Shanghai Liebing Technology Co., Ltd. to construct a cDNA library and perform RNA sequencing and analysis. Key circRNAs were screened and verified at the tissue and cell levels.
[0039] 1.2.4 Fluorescence immunoin situ hybridization
[0040] The circRNA-Slc8a1 probe and kit with Cy3 fluorescence were purchased from Shanghai Jima Pharmaceutical Technology Co., Ltd., and the experiment was completed according to the reagent instructions.
[0041] An appropriate number of TCMK1 cells were seeded in a 24-well plate, washed twice with PBS after 24 hours, 100 μL of 0.1% Buffer A was added to each well, incubated at room temperature for 15 minutes, washed twice with PBS, 100 ul of 2×Buffer C was added, and placed in a 37°C incubator for 30 minutes; Buffer E was incubated in a 73°C water bath for 30 minutes, and then added to the diluted probe, and continued to denature at 73°C for 5 minutes; Buffer C was aspirated, 100 μL of the probe mixture was added to each well, and hybridization was carried out in a light-proof 37°C incubator overnight; the next day, the probe mixture was aspirated, 100 μL of 0.1% Buffer F preheated at 42°C was added to each well for washing for 5 minutes, 100 μL of 2×Buffer C preheated at 42°C was added to each well for washing for 5 minutes, Buffer C was aspirated, and DAPI staining was performed in the dark for 20 minutes, washed twice with PBS, and observed under a microscope.
[0042] 1.2.5 Quantitative real-time PCR (qRT-PCR)
[0043] Analysis by UCSC (http: / / genome.ucsc.edu / ) online database software revealed that the SLC8A1 gene was located on human chromosome 2; according to the SLC8A1 circular RNA information included in the authoritative circular RNA database CircBase (http: / / circrna.org / ), chr2:40655612-40657441 of the SLC8A1 gene formed a closed circular RNA molecule by head-to-tail connection, and its ID in CircBase is hsa_circ_0005232, and its transcription sequence is shown in SEQ ID NO.1, which has 88% sequence homology with mouse circRNA-Slc8a1.
[0044] In order to conduct research experiments, the inventor's laboratory sequenced the mouse circRNA-Slc8a1 transcribed cDNA sequence (circSlc8a1), and its nucleotide sequence is shown in SEQ ID NO.2.
[0045] circRNA-Slc8a1 was selected for further verification by qRT-PCR. Total RNA was reverse transcribed into cDNA using ABscriptⅢ reverse transcriptase (ABclonal, China). The cDNA was used as a template and the reaction system was prepared according to the instructions. Mouse β-actin was used as an internal reference. The results were expressed as Ct values. -△△Ct The expression levels of circRNAs were compared.
[0046] The PCR primer sequences for qRT-PCR are as follows:
[0047]
[0048] The PCR reaction system and reaction procedure are as follows:
[0049] (1) Reversal using ABscriptⅢ reverse transcriptase (ABclonal, China):
[0050]
[0051] (2) According to Takara's RT-qPCR operating procedures, the 10 μl system is configured as follows:
[0052]
[0053] (3) The reaction procedure of RT-qPCR is as follows:
[0054] Pre-denaturation: 95°C, 3 min, cycle 1.
[0055] Polymerase chain reaction: 95°C, 5s; 59°C, 30s; 72°C, 30s; 39 cycles.
[0056] Melting curve: 95°C, 10s; 65°C, 5s; 95°C, 1s; cycle number 1.
[0057] (4) Calculation of relative expression of circSlc8a1: β-actin was used as an internal reference, based on 2 -ΔΔCT To calculate the relative expression of circSlc8a1, three replicate wells were set up, and the average value was calculated according to statistical methods.
[0058] 1.2.7 Culture and transfection of mouse renal tubular epithelial cells
[0059] The cells were cultured in DMEM medium containing 10% fetal bovine serum, 1% penicillin-streptomycin double antibody solution was added, and then cultured in an incubator at 37°C containing 5% CO2. When the cells reached the logarithmic growth phase, they were used for subsequent experiments. DMEM medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin was added to a 6-well plate and cultured in an incubator at 37°C and 5% CO2. TCMK1 cells were transfected with siRNA or its negative control sequence (NC), overexpression plasmid or its control Vector by LipofectamineTM 2000. After 6 hours, the complete culture medium was replaced and cultured for 48 hours to 96 hours. siRNA and NC were purchased from Beijing Qingke Co., Ltd. Vector and overexpression plasmid were purchased from Guangzhou Jisai Biotechnology Co., Ltd.
[0060] The specific sequence of siRNA for circSlc8a1 is:
[0061]
[0062] Overexpression plasmid of circSlc8a1: connected to pLC5-ciR vector by In-fusion cloning. The sequencing peak graph is normal, without impurity peaks or overlapping bands, and the sequence alignment is consistent, indicating that mmu_circRNA_Slc8a1 is successfully inserted into pLC5-ciR and the overexpression vector is successfully constructed. The overexpression plasmid is specifically constructed and provided by Guangzhou Jisai Biotechnology Co., Ltd.
[0063] 1.2.8Western Blot
[0064] After the transfected cells were cultured at 37°C with 5% CO2 for 72h, the cells of each group were collected, the cells were first lysed with RIPA lysis buffer, the supernatant was collected by centrifugation, and the protein concentration was determined. Each group was loaded with equal amounts (30μg), and the proteins were separated by SDS-PAGE electrophoresis, and the proteins were electrotransferred to PVDF membranes. After blocking at room temperature for 2h, anti-rabbit Fn antibody, anti-mouse E-Ca antibody, anti-mouse N-Ca antibody, anti-rabbit α-SMA antibody, anti-rabbit Tgfβ-1 antibody, anti-rabbit Vimintin antibody, anti-rabbit Gpx4 antibody, anti-rabbit xCT antibody, anti-rabbit Vdac1 antibody, and anti-rabbit Tfr antibody were added respectively, and incubated at 4°C overnight. The membrane was washed the next day, incubated with secondary antibodies at room temperature for 1h, and chemiluminescent ECL development, exposure, and imaging were performed after washing the membrane.
[0065] 1.2.9 Detection of intracellular iron ion, SOD, MDA, and GSH activity levels
[0066] After culturing the transfected cells at 37°C with 5% CO2 for 48 h, the cells in each group were collected and the intracellular ferrous ion, SOD, MDA, and GSH activity levels of each group of cells were detected according to the instructions of the intracellular ferrous ion content detection kit (Beijing Solebold Technology Co., Ltd.), the superoxide dismutase (SOD) kit (Biyuntian Biotechnology Co., Ltd.), the malondialdehyde (MDA) assay kit (TBA method) (Beijing Solebold Technology Co., Ltd.), and the GSH and GSSG detection kit (Biyuntian Biotechnology Co., Ltd.).
[0067] 1.2.10 Flow cytometry
[0068] After TCMK1 cells were transfected for 48 hours, the culture medium was discarded and 1 mL of diluted reactive oxygen species (ROS) fluorescent probe DCFH-DA (2,7-dichlorofluorescein diacetate) probe was added. The cells were incubated at 37°C in the dark for 30 minutes, and the cells were collected and finally detected by flow cytometry.
[0069] 1.2.11 Statistical analysis
[0070] The data were processed using the professional software GraphPadPrism8.0.2. In order to meet the statistical requirements, all data were expressed as mean ± standard deviation. In addition, one-way analysis of variance (ANOVA) and multiple tests were used for the analysis of the significance of differences between groups, and the t-test was used for comparison between two groups. P < 0.05 indicates a statistically significant difference.
[0071] 2 Results
[0072] 2.1 Screening and validation of circSlc8a1 in diabetic nephropathy mice
[0073] like Figure 1As shown, 12-week db / db vs db / dm mice showed increased body weight, elevated blood glucose, and increased urine albumin / creatinine ratio ( Figure 1 A, B, C), the difference was statistically significant (P<0.05). Figure 1 D) shows that the db / db mice have smaller glomeruli, sclerosis, diffuse proliferation of mesangium and matrix; PAS staining and Masson staining ( Figure 1 D) showed that the basement membrane of the db / db mouse glomerulus was thicker and the mesangial proliferation was more prominent than that of the db / dm mouse. In addition, Masson staining showed that the db / db mouse samples showed significant renal fibrosis in DN (diabetic nephropathy) mice. The above proved that the DN mouse model was successfully established.
[0074] The above mice were sent for sequencing, and we found 6 upregulated and 12 downregulated circRNAs in the sequencing results by setting the conditions of |log2FC|>0.585 and FDR<0.05 ( Figure 1 E): The up-regulated ones are circRad52, circPtprk, circAcat3, circSlc8a1, circLuc7l, and circKansl1l-1. Among them, circSlc8a1 has the highest expression level, so circslc8a1 will be the subject of subsequent research.
[0075] Paraffin sections ( Figure 1 F) The results showed that circSlc8a1 was mainly localized in the renal tubules and renal interstitium, and the fluorescence intensity of the renal tubules and renal interstitium of DN mice was significantly stronger than that of control mice. This suggests that circSlc8a1 may be associated with renal tubular epithelial-mesenchymal transition (EMT) and interstitial fibrosis in DN. Moreover, circSlc8a1 was significantly highly expressed in TCMK1 cells ( Figure 1 G).
[0076] In high glucose-induced renal tubular epithelial cells, FISH and nuclear-cytoplasmic separation qRT-PCR revealed that circSlc8a1 was indeed localized in the cytoplasm ( Figure 1 H, 1I).
[0077] The nucleotide sequence of circSlc8a1 is:
[0078] 2.2 RNA-seq analysis after overexpression of circSlc8a1
[0079] RNA-seq results ( Figure 2 ) showed that circSlc8a1 was related to iron metabolism and ferroptosis. Combined with the previous suggestions, we speculated that circSlc8a1 may be related to EMT-induced fibrosis and ferroptosis caused by metabolic disorders in diabetic nephropathy.
[0080] 2.3 Knockdown / overexpression of circSlc8a1 affects EMT-induced fibrosis in renal tubular epithelial cells
[0081] Based on the results of kidney staining of circSlc8a1, it was inferred that high expression of circSlc8a1 was associated with EMT and renal interstitial fibrosis. Therefore, we designed three siRNAs and one plasmid targeting circSlc8a1 to study whether it promotes EMT and affects DN fibrosis by knocking down / overexpressing the expression of circSlc8a1.
[0082] like Figure 3 As shown in the figure, both WB and IF experiments show that after knocking down circSlc8a1, EMT marker proteins α-smooth muscle actin (α-SMA), vimentin (Vimenti), and N-cadherin (N-Ca) were significantly inhibited, and epithelial marker proteins (E-cadherin, E-Ca) increased. However, fibrosis-related proteins such as transforming growth factor β1 (TGFβ-1) and fibrosis-related collagen (Fn) decreased significantly, indicating that circSlc8a1 regulates the EMT of DN and promotes the process of renal fibrosis.
[0083] 2.4 Knockdown / overexpression of circSlc8a1 affects ferroptosis of renal tubular epithelial cells
[0084] RNA-seq analysis showed that high expression of circSlc8a1 was associated with ferroptosis caused by iron ion metabolic disorder. To this end, we knocked down / overexpressed circSlc8a1 to study whether circSlc8a1 would promote iron metabolic disorder and thus cause ferroptosis. Figure 4 As shown in the figure, after knocking down circSlc8a1, intracellular ferrous ions, MDA activity, ROS, and SOD levels were significantly reduced, while GSH levels were significantly increased, the expression levels of GPX4 and xCT proteins in the cells were significantly increased, while the expression levels of Tfr and Vdac1 proteins were significantly decreased, indicating that circSlc8a1 regulates iron metabolism and promotes ferroptosis of renal tubular epithelial cells.
[0085] 3 Discussions
[0086] In summary, this study showed that circSlc8a1 promoted fibrosis and ferroptosis induced by epithelial-mesenchymal transition (EMT) in renal tubular epithelial cells, and knockdown of circSlc8a1 had a protective effect on renal tubular epithelial cells, which is expected to be a potential target for the diagnosis and treatment of DN.
Claims
1. Use of a reagent for detecting biomarkers in a sample in the preparation of a product for diagnosing diabetic nephropathy, characterized in that: The biomarker is circRNA-Slc8a1.
2. The use according to claim 1, characterized in that: Compared with normal controls, the expression level of circRNA-Slc8a1 was upregulated in patients.
3. The use according to claim 2, characterized in that: The content of circRNA-Slc8a1 in the patient's test samples was detected by total RNA extraction, reverse transcription, and quantitative PCR.
4. Use of a circRNA-Slc8a1 expression inhibitor in the preparation of a drug for preventing and treating diabetic nephropathy, wherein the circRNA-Slc8a1 expression inhibitor is selected from siRNA, and the sequence of the siRNA is: Sense strand sequence: 5'-GAUGAAAUAGUGUUGGAGC-3', Antisense strand sequence: 5′-GCUCCAACACUAUUUCAUC-3′.
5. Application of circRNA-Slc8a1 as a target in screening drugs for the prevention and treatment of diabetic nephropathy.
6. The use according to claim 5, characterized in that: The drug inhibits the expression of circRNA-Slc8a1.
